Nuclidium AGBasel-based NUCLIDIUM AG has successfully closed a Series B financing round of CHF 79 million (EUR 84 million) to advance the development of its copper-based radiopharmaceutical platform. The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR, a company of the Intesa Sanpaolo Group.
Tag Archive for: Kurma
Kurma Partners announced a first closing of its new Biofund IV at €140m targeted to raise €250m to finance 16-20 life science companies.
Swiss antibody specialist Memo Therapeutics AG has added CHF20m to its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.
ImCheck Therapeutics located in Marseille, France, announced today the close of a EUR 96 million (USD 103 million) financing, co-led by Earlybird and Andera Partners. Kurma Partners, Eurazeo, Gimv, Pfizer, Bpifrance through its Innobio 2 and Large Venture funds, Wellington Partners, Pureos Bioventures, Agent Capital and Alexandria Venture Investments are invested already. Invus and The Leukemia & Lymphoma
Society Therapy Acceleration Program also joined the round as new investors.